Talaris Therapeutics Announces Leadership Transition
May 26, 2023 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and...
Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan
February 16, 2023 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based...
Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update
November 10, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual...
Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance
November 07, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
October 20, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting
October 17, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
October 04, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
September 21, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
September 06, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...